SecBot SecBot
SECBOTREPLAY Home › Report › BIIB

BIIB · Needham double-upgraded Biogen (BIIB) from Hold to Buy on June 8,…

BIOGEN INC. · ANALYST-UPGRADE filed

At the news

BULLISHIMPACT 2/10

ANALYST-UPGRADE filed

Needham double-upgraded Biogen (BIIB) from Hold to Buy on June 8, setting a $255 price target, implying 30.5% upside from the current $195.34. The firm has a 45% accuracy rate on 20 scored calls with an average return of -3.9%, placing it below average among covering firms. Consensus on BIIB is bullish: 27 of 44 analysts rate it Buy (61%), 16 Hold, and 1 Sell. The mean price target is $219.44, median $215, with a high of $300 and low of $150. Needham's $255 target sits above the consensus mean. Over the past 30 days, BIIB has seen 1 upgrade and 0 downgrades, but EPS revisions for the current year have been negative, 10 downward revisions vs 0 upward. The next earnings report is due July 29, about 7 weeks out. Institutional activity shows a major new position from Norges Bank ($464M) and FMR LLC more than doubling its stake (+632%), while short interest is elevated at 66.8% of float. No insider or congressional trades were recorded. The double upgrade from a below-average-accuracy firm is a contrarian signal but lacks the high-accuracy conviction to warrant a large impact adjustment.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access